FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3187788327> ?p ?o ?g. }

• W3187788327 abstract "Abstract Funding Acknowledgements Type of funding sources: None. Background The use of Left Ventricular Assist Devices (LVAD) has noticeably improved the survival for patients with advanced heart failure. However, this treatment is associated with significant adverse effects. Personalisation of antiplatelet therapy is a key in control and reduction of bleeding/thromboembolic complications of this treatment. However, ISHLT and the manufacturer still recommend unified treatment of 150 mg of acetylsalicylic acid for all LVAD patients. In our centre, we base the treatment decision on clinical picture and patient’s responsiveness to antiplatelet therapy. The treatment of choice is acetylsalicylic acid in doses 37.5 mg (1 patient), 75 mg (25 patients) and 150 mg (33 patients). For patients unresponsive or intolerant to acetylsalicylic acid we use 75 mg of clopidogrel, currently 9 patients. 1 patient receives both, 75 mg clopidogrel and 75 mg acetylsalicylic acid. Purpose To gain a better understanding of the platelets function and patients responses to antiplatelet therapy. In aim to reduce the prevalence of bleeding/thromboembolic related adverse events in LVAD patients, and therefore improve patients outcome. Methods In 2020, we decided to introduce a structured/test-based approach to antiplatelet therapy in this patients group. With the use of Multiplate Electrode Aggregometry (MEA) we have attempted to diagnose platelet disorders and monitor effectiveness of antiplatelet therapy. Based on MEA platlets inhibition test we were able to tailor the therapy. The retrospective audit was conducted with inclusion criteria; 1. Thromboembolic events include pump thrombosis and any other ischemic complications. Bleeding events contains gastrointestinal (GI) and central nervous system (CNS) events. 2. Any thromboembolic and bleeding events after starting antiplatelet therapy, in the first year after LVAD implantation Results The tables below presents reduction in both thromboembolic and bleeding complications. Conclusion Presented data can be interpreted that, the test-based approach to antiplatelet therapy may be beneficial in limiting the adverse effects of LVAD therapy. However, it needs to be acknowledged that the observation was carried out on a small group of the patients, over a short period of time. Therefore, an extended period of observation is recommended to obtain further data." @default.
• W3187788327 created "2021-08-16" @default.
• W3187788327 creator A5016126033 @default.
• W3187788327 creator A5017594575 @default.
• W3187788327 creator A5040139275 @default.
• W3187788327 creator A5050682099 @default.
• W3187788327 creator A5067717800 @default.
• W3187788327 creator A5072000734 @default.
• W3187788327 creator A5081021514 @default.
• W3187788327 date "2021-07-01" @default.
• W3187788327 modified "2023-09-27" @default.
• W3187788327 title "Use of multiplate electrode aggregometry for personalisonalisation of antiplatelet therapy in left ventricular assisst device patients" @default.
• W3187788327 doi "https://doi.org/10.1093/eurjcn/zvab060.016" @default.
• W3187788327 hasPublicationYear "2021" @default.
• W3187788327 type Work @default.
• W3187788327 sameAs 3187788327 @default.
• W3187788327 citedByCount "0" @default.
• W3187788327 crossrefType "journal-article" @default.
• W3187788327 hasAuthorship W3187788327A5016126033 @default.
• W3187788327 hasAuthorship W3187788327A5017594575 @default.
• W3187788327 hasAuthorship W3187788327A5040139275 @default.
• W3187788327 hasAuthorship W3187788327A5050682099 @default.
• W3187788327 hasAuthorship W3187788327A5067717800 @default.
• W3187788327 hasAuthorship W3187788327A5072000734 @default.
• W3187788327 hasAuthorship W3187788327A5081021514 @default.
• W3187788327 hasBestOaLocation W31877883271 @default.
• W3187788327 hasConcept C126322002 @default.
• W3187788327 hasConcept C164705383 @default.
• W3187788327 hasConcept C197934379 @default.
• W3187788327 hasConcept C2777628954 @default.
• W3187788327 hasConcept C2777849778 @default.
• W3187788327 hasConcept C2778198053 @default.
• W3187788327 hasConcept C2778774980 @default.
• W3187788327 hasConcept C2779326848 @default.
• W3187788327 hasConcept C2780868729 @default.
• W3187788327 hasConcept C2909112448 @default.
• W3187788327 hasConcept C71924100 @default.
• W3187788327 hasConceptScore W3187788327C126322002 @default.
• W3187788327 hasConceptScore W3187788327C164705383 @default.
• W3187788327 hasConceptScore W3187788327C197934379 @default.
• W3187788327 hasConceptScore W3187788327C2777628954 @default.
• W3187788327 hasConceptScore W3187788327C2777849778 @default.
• W3187788327 hasConceptScore W3187788327C2778198053 @default.
• W3187788327 hasConceptScore W3187788327C2778774980 @default.
• W3187788327 hasConceptScore W3187788327C2779326848 @default.
• W3187788327 hasConceptScore W3187788327C2780868729 @default.
• W3187788327 hasConceptScore W3187788327C2909112448 @default.
• W3187788327 hasConceptScore W3187788327C71924100 @default.
• W3187788327 hasIssue "Supplement_1" @default.
• W3187788327 hasLocation W31877883271 @default.
• W3187788327 hasOpenAccess W3187788327 @default.
• W3187788327 hasPrimaryLocation W31877883271 @default.
• W3187788327 hasRelatedWork W1996876262 @default.
• W3187788327 hasRelatedWork W2074171802 @default.
• W3187788327 hasRelatedWork W2080681036 @default.
• W3187788327 hasRelatedWork W2125804349 @default.
• W3187788327 hasRelatedWork W2160363106 @default.
• W3187788327 hasRelatedWork W2984953920 @default.
• W3187788327 hasRelatedWork W4251924419 @default.
• W3187788327 hasRelatedWork W4318755704 @default.
• W3187788327 hasRelatedWork W2189576330 @default.
• W3187788327 hasRelatedWork W2527719101 @default.
• W3187788327 hasVolume "20" @default.
• W3187788327 isParatext "false" @default.
• W3187788327 isRetracted "false" @default.
• W3187788327 magId "3187788327" @default.
• W3187788327 workType "article" @default.